XORTX has two lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic
ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, presenting in up to 18% of this population1.
Ovary syndrome is a common gynaecological problem affecting 25 percent of general population.
ovarian syndrome (PCOS) is one of the most common endocrine disorder affecting 5-10% of the women in the reproductive age group.4 Common features of PCOS are seborrhea, acne, hirsutism, acanthosis nigricans, alopecia and if left unrecognized or untreated it can lead to metabolic, reproductive, psychological and neoplastic complications.5 Cutaneous changes are one of the earliest manifestations of PCOS, and as the skin is visible and accessible organ in the body, observation of the former can be of extreme value to the clinician in diagnosing PCOS.
Amenontiea associated with bilateral polycystic
Clomiphene, metformin, or both for infertility in the polycystic
ovary syndrome is a major cause of infertility due to anovulation.
ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders with a prevalence of approximately 60-70% in Chinese obese women of reproductive age. The common manifestations of PCOS are oligomenorrhea, chronic anovulation, hyperandrogenism, hyperinsulinemia, and polycystic
ovaries on ovarian ultrasonography. PCOS increases the risks of type 2 diabetes, cardiovascular disease, endometrial cancer, and ovarian cancer., The pathogenesis of PCOS remains unclear, although it is considered to be the result of interaction between genetic, environmental, and lifestyle factors.
Since 2003, large amount of literature has been published questioning the Rotterdam criteria of polycystic
ovarian morphology and its utility as a marker of PCOS.
ovary syndrome, SNP microarray, Whole exome sequencing.
For the diagnosis of PCOS, ultrasound can be used to check for polycystic
ovaries and endometrial thickness.
M2 EQUITYBITES-April 25, 2018-PKD Foundation wins US FDA approval for JYNARQUE to treat polycystic